急性膽囊炎市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、原因、診斷程序、治療方法、最終用戶、地區和競爭格局分類），2021-2031年

全球急性膽囊炎市場預計將從2025年的26.4億美元成長到2031年的37.3億美元，複合年成長率（CAGR）為5.93%。這一成長主要受急性膽囊炎治療需求的推動。急性膽囊炎是由膽結石引起的膽囊管阻塞所致，需要緊急診斷和治療。市場擴張很大程度上是由於膽結石發生率的上升，膽結石的發生率上升與全球人口老化和肥胖率上升密切相關。此外，微創手術（如腹腔鏡膽囊切除術和機器人輔助膽囊切除術）的廣泛應用也有助於患者復原。

然而，限制市場效率的一大障礙是標準影像檢查結果經常存在歧義，這可能導致治療延誤和併發症風險增加。早期診斷的不確定性造成了醫療連續性方面的重大缺口。美國感染疾病學會 (IDSA) 的一項案例研究凸顯了這個問題：2024 年，腹部超音波對疑似急性膽囊炎病例的中位敏感性僅為 73%。此類數據強調了迫切需要能夠克服當前標準影像檢查通訊協定局限性的更先進的診斷技術。

市場促進因素

市場收入的主要促進因素是膽結石及相關疾病盛行率的不斷上升，這直接導致全球膽囊切除術數量的增加。生活方式的改變和人口趨勢，尤其是肥胖，進一步推動了這一趨勢，使更多人群易患膽道疾病，並迫使醫療系統擴大其急診護理能力。根據美國國立衛生研究院 (NIH) 於 2025 年 10 月發布的題為《2000-2024 年全球普通人群膽結石率估計》的系統性綜述，全球膽結石率估計為 5.86%，這確保了對急診護理的穩定需求，並為市場的長期穩定需求奠定了基礎。

同時，腹腔鏡和機器人輔助膽囊切除術的興起正在重塑醫療領域，並透過引入先進的手術器械推動市場價值的成長。這些微創技術如今已成為黃金標準，由於住院時間縮短和併發症發生率降低，手術量顯著增加。例如，Intuitive Surgical公司於2025年1月發布的「2024年第四季及全年初步快報」顯示，使用達文西手術系統進行的手術數量年增17%。然而，經濟挑戰依然存在。美國外科醫學會（ACS）2025年4月的研究發現，機器人膽囊切除術的耗材成本顯著高於傳統腹腔鏡手術，分別為1,309美元和534美元。這凸顯了常用標準手術與採用高附加價值技術的介入手術之間的市場分化。

市場挑戰

全球急性膽囊炎市場的主要限制因素是傳統影像技術固有的診斷不確定性。早期診斷準確性的不足造成了患者照護的瓶頸，並常常導致醫生對是否需要緊急手術猶豫不決。當腹部超音波等關鍵診斷工具提供不確定結果時，醫生通常會選擇保守治療而非膽囊切除術。這會延誤手術（該市場的主要收入來源），並因患者住院時間延長而加重醫療資源的負擔。

這種診斷上的不確定性導致許多患者最初因檢查結果不確定而接受非手術治療，最終治療失敗率很高。根據美國外科醫師學會2024年的數據，78%因急性膽囊炎症狀而未接受手術便出院的患者最終需要緊急入院接受膽囊切除術。這一趨勢凸顯了市場效率低下的一個顯著問題：初次就診時未能準確診斷和治療會導致醫療服務碎片化，錯失治療良機，從而阻礙手術治療方案的順利推廣和整體市場成長。

市場趨勢

一個值得關注的趨勢是超音波引導下膽囊引流術（EUS-GBD）的興起，特別是腔內金屬支架（LAMS）的應用，為不合格手術的患者提供了一種創新方法。該技術為經皮膽囊造瘻術提供了一種微創替代方案，適用於高風險老年患者和合併多種疾病、無法耐受標準膽囊切除術的患者，透過提供內部引流來改善患者的生活品質。 2024年2月發表於《診斷學》（Diagnostics）雜誌的一項題為“使用腔內壓迫金屬支架進行EUS引導下膽囊引流治療急性膽囊炎”的研究支持了該技術的有效性，該研究報告稱，在高風險患者中，LAMS置入的技術成功率高達94%，使其成為一種有效的標準治療方法。

同時，人工智慧（AI）在診斷影像中的應用正在克服傳統超音波的局限性，並為早期精準檢測樹立新的標準。利用機器學習實現病灶辨識和膽囊分割的自動化，能夠幫助醫療服務提供者減少操作者間的差異，並彌補傳統影像技術靈敏度低的不足，從而加快干預決策。發表於2024年2月《生物醫學科學與技術研究期刊》（Biomedical Journal of Scientific & Technical Research）的一項題為「基於人工智慧的膽囊分割技術在急性膽囊炎診斷中的應用」的研究表明，應用特定的AI模型可實現84.09%的診斷準確率，使其成為靈敏度不足的超音波的理想敏感性。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球急性膽囊炎市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（結石性急性膽囊炎與非結石性急性膽囊炎）
  • 依病因分類（膽結石、腫瘤、膽管阻塞、微生物感染、其他）
  • 透過診斷程序（超音波、膽道閃爍顯像、 電腦斷層掃描、ERCP（內視鏡逆行性胰造影）、其他）
  • 依治療方法（手術與非手術）
  • 依最終使用者（醫院/診所、門診手術中心、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美急性膽囊炎市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲急性膽囊炎市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區急性膽囊炎市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲急性膽囊炎市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲急性膽囊炎市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球急性膽囊炎市場：SWOT分析

第14章 波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Boston Scientific Corporation
• Fresenius Kabi AG
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Limited
• Merck & Co. Inc.
• Becton, Dickinson and Company
• Simulab Corporation
• AbbVie Inc.
• Fortimedix Surgical BV

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Acute Cholecystitis Market is projected to expand from USD 2.64 Billion in 2025 to USD 3.73 Billion by 2031, reflecting a CAGR of 5.93%. This growth is rooted in the management of acute gallbladder inflammation, a condition primarily triggered by gallstone obstruction of the cystic duct that necessitates urgent diagnosis and treatment. Market expansion is heavily influenced by the escalating incidence of gallstone disease, which is closely tied to an aging global demographic and rising obesity rates, alongside the broader application of minimally invasive surgical options like laparoscopic and robotic cholecystectomy that enhance patient recovery.

Conversely, a significant hurdle limiting market efficiency is the ambiguity often found in standard imaging results, which can result in treatment delays and higher complication risks. This lack of initial diagnostic clarity represents a substantial gap in the care continuum. Highlighting this issue, the Infectious Diseases Society of America reported in 2024 that the median sensitivity of abdominal ultrasound for detecting suspected acute cholecystitis was only 73%. Such data emphasizes the critical need for superior diagnostic technologies to surpass the constraints of current standard imaging protocols.

Market Driver

The primary catalyst for market revenue is the growing prevalence of gallstones and related disorders, which directly fuels the global volume of cholecystectomy surgeries. This momentum is further accelerated by lifestyle changes and demographic trends, specifically obesity, which make larger populations susceptible to biliary issues, thereby forcing healthcare systems to expand their acute management capacities. As noted by the National Institutes of Health in an October 2025 systematic review titled 'Estimating global prevalence of gallbladder stones in general population from 2000 to 2024,' the global prevalence of gallstones was determined to be 5.86%, ensuring a steady demand for acute care and underpinning long-term market stability.

In parallel, the shift toward laparoscopic and robotic cholecystectomy is redefining the therapeutic sector, increasing market value through the deployment of sophisticated surgical tools. These minimally invasive methods are now the gold standard due to their ability to shorten hospital stays and lower complication rates, which facilitates higher procedural volume. For instance, Intuitive Surgical's 'Preliminary Fourth Quarter and Full Year 2024 Results' from January 2025 indicated a 17% year-over-year increase in procedures using da Vinci systems. However, economic considerations persist; an April 2025 American College of Surgeons study revealed that robotic cholecystectomy involves significantly higher disposable costs at $1,309 compared to $534 for traditional laparoscopic methods, delineating a market split between high-volume standard care and premium technological interventions.

Market Challenge

The primary obstacle restricting the Global Acute Cholecystitis Market is the diagnostic uncertainty inherent in conventional imaging techniques. This lack of early precision forms a bottleneck in patient care, frequently leading to hesitation regarding the need for immediate surgery. When primary diagnostic tools like abdominal ultrasound fail to yield clear results, physicians often default to conservative management instead of performing a cholecystectomy, delaying the market's primary revenue-generating procedure and straining healthcare resources through extended hospitalizations.

The consequences of this diagnostic ambiguity are manifested in high treatment failure rates among patients initially treated non-surgically due to inconclusive tests. Data from the American College of Surgeons in 2024 showed that 78% of patients with acute cholecystitis symptoms who were discharged without surgery eventually required emergency readmission for a cholecystectomy. This pattern highlights a major market inefficiency, where the failure to accurately diagnose and treat the condition during the initial visit results in fragmented care and missed therapeutic opportunities, thereby hindering the seamless adoption of surgical solutions and overall market growth.

Market Trends

A significant trend is the rise of Endoscopic Ultrasound-Guided Gallbladder Drainage (EUS-GBD), specifically using Lumen-Apposing Metal Stents (LAMS), as a transformative approach for patients ineligible for surgery. This technique provides a minimally invasive substitute for percutaneous cholecystostomy, catering to high-risk elderly or comorbid patients unable to tolerate standard cholecystectomy, thereby improving quality of life by internalizing drainage. Validating this approach, a February 2024 study in Diagnostics titled 'EUS-Guided Gallbladder Drainage Using a Lumen-Apposing Metal Stent for Acute Cholecystitis' reported a 94% technical success rate for LAMS placement in high-risk groups, establishing it as an effective therapeutic standard.

Concurrently, the incorporation of Artificial Intelligence (AI) into diagnostic imaging is setting new benchmarks for early and precise detection, addressing the shortcomings of traditional ultrasound. By utilizing machine learning to automate pathology recognition and gallbladder segmentation, medical providers can mitigate inter-operator variability and the low sensitivity associated with standard imaging, facilitating quicker intervention decisions. As reported in the Biomedical Journal of Scientific & Technical Research in February 2024, the application of specific AI models in the study 'Usage of Artificial Intelligence in Gallbladder Segmentation to Diagnose Acute Cholecystitis' achieved a diagnostic accuracy of 84.09%, presenting a superior alternative to the lower sensitivity found in manual ultrasonography.

Key Market Players

• Boston Scientific Corporation
• Fresenius Kabi AG
• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Limited
• Merck & Co. Inc.
• Becton, Dickinson and Company
• Simulab Corporation
• AbbVie Inc.
• Fortimedix Surgical BV

Report Scope

In this report, the Global Acute Cholecystitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Cholecystitis Market, By Type

• Calculous Acute Cholecystitis v/s Acalculous Acute Cholecystitis

Acute Cholecystitis Market, By Cause

• Gall Bladder Stones
• Tumor
• Bile Duct Blockage
• Microbial Infection
• Others

Acute Cholecystitis Market, By Diagnostic Procedure

• Ultrasonography
• Cholescintigraphy
• CT Scan
• ERCP (Endoscopic Retrograde Cholangiopancreatography)
• Others

Acute Cholecystitis Market, By Treatment

• Surgical v/s Non-Surgical

Acute Cholecystitis Market, By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Acute Cholecystitis Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acute Cholecystitis Market.

Available Customizations:

Global Acute Cholecystitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acute Cholecystitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Calculous Acute Cholecystitis v/s Acalculous Acute Cholecystitis)
  • 5.2.2. By Cause (Gall Bladder Stones, Tumor, Bile Duct Blockage, Microbial Infection, Others)
  • 5.2.3. By Diagnostic Procedure (Ultrasonography, Cholescintigraphy, CT Scan, ERCP (Endoscopic Retrograde Cholangiopancreatography), Others)
  • 5.2.4. By Treatment (Surgical v/s Non-Surgical)
  • 5.2.5. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Acute Cholecystitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Cause
  • 6.2.3. By Diagnostic Procedure
  • 6.2.4. By Treatment
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acute Cholecystitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Cause
      • 6.3.1.2.3. By Diagnostic Procedure
      • 6.3.1.2.4. By Treatment
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Acute Cholecystitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Cause
      • 6.3.2.2.3. By Diagnostic Procedure
      • 6.3.2.2.4. By Treatment
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Acute Cholecystitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Cause
      • 6.3.3.2.3. By Diagnostic Procedure
      • 6.3.3.2.4. By Treatment
      • 6.3.3.2.5. By End User

7. Europe Acute Cholecystitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Cause
  • 7.2.3. By Diagnostic Procedure
  • 7.2.4. By Treatment
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Acute Cholecystitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Cause
      • 7.3.1.2.3. By Diagnostic Procedure
      • 7.3.1.2.4. By Treatment
      • 7.3.1.2.5. By End User
  • 7.3.2. France Acute Cholecystitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Cause
      • 7.3.2.2.3. By Diagnostic Procedure
      • 7.3.2.2.4. By Treatment
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Acute Cholecystitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Cause
      • 7.3.3.2.3. By Diagnostic Procedure
      • 7.3.3.2.4. By Treatment
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Acute Cholecystitis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Cause
      • 7.3.4.2.3. By Diagnostic Procedure
      • 7.3.4.2.4. By Treatment
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Acute Cholecystitis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Cause
      • 7.3.5.2.3. By Diagnostic Procedure
      • 7.3.5.2.4. By Treatment
      • 7.3.5.2.5. By End User

8. Asia Pacific Acute Cholecystitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Cause
  • 8.2.3. By Diagnostic Procedure
  • 8.2.4. By Treatment
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Acute Cholecystitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Cause
      • 8.3.1.2.3. By Diagnostic Procedure
      • 8.3.1.2.4. By Treatment
      • 8.3.1.2.5. By End User
  • 8.3.2. India Acute Cholecystitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Cause
      • 8.3.2.2.3. By Diagnostic Procedure
      • 8.3.2.2.4. By Treatment
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Acute Cholecystitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Cause
      • 8.3.3.2.3. By Diagnostic Procedure
      • 8.3.3.2.4. By Treatment
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Acute Cholecystitis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Cause
      • 8.3.4.2.3. By Diagnostic Procedure
      • 8.3.4.2.4. By Treatment
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Acute Cholecystitis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Cause
      • 8.3.5.2.3. By Diagnostic Procedure
      • 8.3.5.2.4. By Treatment
      • 8.3.5.2.5. By End User

9. Middle East & Africa Acute Cholecystitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Cause
  • 9.2.3. By Diagnostic Procedure
  • 9.2.4. By Treatment
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Acute Cholecystitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Cause
      • 9.3.1.2.3. By Diagnostic Procedure
      • 9.3.1.2.4. By Treatment
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Acute Cholecystitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Cause
      • 9.3.2.2.3. By Diagnostic Procedure
      • 9.3.2.2.4. By Treatment
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Acute Cholecystitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Cause
      • 9.3.3.2.3. By Diagnostic Procedure
      • 9.3.3.2.4. By Treatment
      • 9.3.3.2.5. By End User

10. South America Acute Cholecystitis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Cause
  • 10.2.3. By Diagnostic Procedure
  • 10.2.4. By Treatment
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Acute Cholecystitis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Cause
      • 10.3.1.2.3. By Diagnostic Procedure
      • 10.3.1.2.4. By Treatment
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Acute Cholecystitis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Cause
      • 10.3.2.2.3. By Diagnostic Procedure
      • 10.3.2.2.4. By Treatment
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Acute Cholecystitis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Cause
      • 10.3.3.2.3. By Diagnostic Procedure
      • 10.3.3.2.4. By Treatment
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Acute Cholecystitis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boston Scientific Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Fresenius Kabi AG
• 15.3. Pfizer Inc
• 15.4. Teva Pharmaceutical Industries Ltd.
• 15.5. Glenmark Pharmaceuticals Limited
• 15.6. Merck & Co. Inc.
• 15.7. Becton, Dickinson and Company
• 15.8. Simulab Corporation
• 15.9. AbbVie Inc.
• 15.10. Fortimedix Surgical BV

16. Strategic Recommendations

17. About Us & Disclaimer